Butterfly Network/$BFLY
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Butterfly Network
Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound. Powered by its proprietary Ultrasound-on-Chip technology, its solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional's pocket with a combination of cloud-connected software and hardware technology that is easily accessed through a mobile application. Butterfly iQ+ is an ultrasound device that can perform whole-body imaging in a single handheld probe using semiconductor technology. The company operates in one reportable segment, which includes all activities related to the development, manufacture, and sale of the Company's products, software, and other services.
- Ticker
- $BFLY
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 220
- Headquarters
- Burlington, United States
- Website
- www.butterflynetwork.com
BFLY Metrics
BasicAdvanced
$1.6B
-
-$0.21
2.04
-
Price and volume
Market cap
$1.6B
Beta
2.04
52-week high
$10.21
52-week low
$1.90
Average daily volume
5.1M
Financial strength
Current ratio
3.584
Quick ratio
2.55
Long term debt to equity
0.084
Total debt to equity
0.1
Interest coverage (TTM)
-36.02%
Profitability
EBITDA (TTM)
-41.642
Gross margin (TTM)
70.26%
Net profit margin (TTM)
-43.56%
Operating margin (TTM)
-36.09%
Effective tax rate (TTM)
-0.12%
Revenue per employee (TTM)
$560,000
Management effectiveness
Return on assets (TTM)
-9.62%
Return on equity (TTM)
-27.65%
Valuation
Price to revenue (TTM)
12.781
Price to book
8.8
Price to tangible book (TTM)
9.12
Price to free cash flow (TTM)
-57.182
Free cash flow yield (TTM)
-1.75%
Free cash flow per share (TTM)
-0.106
Growth
Revenue change (TTM)
39.35%
Earnings per share change (TTM)
-38.56%
3-year revenue growth (CAGR)
21.71%
3-year earnings per share growth (CAGR)
-30.08%
What the Analysts think about BFLY
Analyst ratings (Buy, Hold, Sell) for Butterfly Network stock.
Analyst projections of the future price of Butterfly Network stock.
Bulls say / Bears say
Q3 revenue rose 52% year on year to $32.6 million, beating guidance, and Butterfly raised its 2026 revenue outlook to $123 million–$126 million, implying 26%–29% growth. (Business Wire)
Adjusted gross margin reached 73%, while the adjusted EBITDA loss narrowed 85% to $1.2 million. This points to improving operating leverage as higher-margin revenue grows. (Business Wire)
Butterfly’s Embedded model is beginning to reach commercial use: its first partner product launched in October, and the company signed five seven-figure and ten six-figure enterprise deals in Q3. (Business Wire)
The company remains loss-making: Q3 net loss was $12.8 million, and management still expects a full-year adjusted EBITDA loss of $12 million–$15 million. (Business Wire)
Embedded revenue depends on partner milestones and can vary sharply between quarters. Butterfly’s Q4 revenue outlook implies only about 3% year-on-year growth at the midpoint, leaving near-term momentum exposed to timing shifts. (Business Wire, Stock Analysis)
Butterfly has established an at-the-market equity programme of up to $150 million. If used, issuing shares could dilute existing investors. (Stock Analysis)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
BFLY Financial Performance
Revenues and expenses
BFLY Earnings Performance
Company profitability
Upcoming events
No upcoming events
BFLY News
AllArticlesVideos
Butterfly Network Q3 Earnings Call Highlights
MarketBeat1 week ago
Butterfly Network to Present at UBS Global Healthcare Conference on November 10, 2026
Business Wire1 week ago
The Edward Via College of Osteopathic Medicine (VCOM) and Butterfly Network Announce Long-Term Alliance to Build New Model for Ultrasound Education
Business Wire3 weeks ago
Funds containing BFLY
Fund name | Fund size | $BFLY weighting |
|---|---|---|
ARK Genomic Revolution€AAKG | $123M | 1.83% |
ARK Genomic Revolution£ARCG | $123M | 1.83% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.05% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.05% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.